Erasca reported its Q4 2021 financial results, highlighting a strong cash position of $459.2 million and progress in its clinical programs, including ERAS-007, ERAS-601, and ERAS-801.
Initiated three HERKULES clinical trials in 2021 evaluating ERAS-007.
Entered into a clinical trial collaboration and supply agreement with Lilly for cetuximab.
Nominated ERAS-3490, a highly CNS-penetrant KRAS G12C inhibitor.
Received IND clearance of ERAS-801 for the treatment of patients with recurrent glioblastoma multiforme.
Erasca expects its current cash, cash equivalents, and investments balance to fund operations into 2024.
Analyze how earnings announcements historically affect stock price performance